Formosa Pharmaceuticals Investors
Corporate Governance
Board of Directors
Major Policies
- Article of incorporation
- Corporate governance structure
- Management of assets
- Management of related party transactions
- Management of the prevention of insider trading
- Procedures and methods for acquiring or disposing of assets
- Ethical corporate management best practice principles acquiring or disposing of assets
- Code of ethics
- Procedures for election of directors
- Operational procedures for endorsements and guarantees
- Corporate governance best practice principles
- Corporate sustainable development best practice principles
- Operational procedures for loaning funds to others
- Rules of procedure for shareholders meetings
Major Resolutions
News Highlight
Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
2024-11-28
Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain TAIPEI – November 28, 2024 – Taiwan-based Formosa Pharmaceuticals
